Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user shared their positive experience with a hair transplant at Eugenix in India, noting the professionalism and natural results. They mentioned using 2815 grafts and discussed the clinic's controversial name, but did not mention using specific treatments like Minoxidil or finasteride.

The conversation discusses the availability and effectiveness of novel topical anti-androgens for hair loss, mentioning treatments like Breezula, GT20029, pyrilutamide, KX826, and RU58841. Users express skepticism about the effectiveness of these treatments and note that some are already available.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

The user has been using topical finasteride and minoxidil since 2021 and is exploring other hair treatment companies like Xyon and Happy Head due to dissatisfaction with the current product's smell. They question the authenticity of consultations from these companies, suspecting they might be automated.

The conversation discusses the impact of H. pylori on nutrient absorption, specifically iron and B12. It also mentions checking serum DHT levels as a potential solution.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

A user plans a drug-free hair transplant while waiting for future treatments like stem cell therapies, which are projected to be available between 2028 and 2030. Many users express skepticism about the availability of new treatments, suggesting that relying on them is risky and that finasteride remains the most effective option.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

The conversation is about a person considering making their own topical finasteride to avoid side effects from oral use. They discuss potential methods and ingredients, including cayenne pepper extract, rosemary, and coconut oil, and seek advice on effectiveness and alternatives like light therapy or dermarolling.

The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

The conversation is about creating a custom hair loss treatment by mixing Kirkland Minoxidil with latanoprost, sandalore, valproic acid, and RU58841. The user is seeking suggestions or advice on this mixture.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.